GlassScriptPhysician profile
Danielle Barbaro
NPI 1194224493
$739.98
in general payments reported to CMS, 2019-2025
13 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $263 · 2023: $173 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $194.98 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.92 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $92.14 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $80.10 | 2022-2025 | Abilify Maintena, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $50.61 | 2025 | Breztri |
| Lilly USA, LLC | $35.09 | 2021-2025 | Zepbound |
| Glaxosmithkline, LLC. | $32.90 | 2022-2025 | Trelegy Ellipta |
| Abbott Laboratories | $24.88 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.18 | 2025 | Recorlev |
| Novo Nordisk INC | $17.83 | 2025 | Ozempic |
| Indivior INC. | $16.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.50 | 2021 | |
| Amarin Pharma, INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Barbaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.